Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 701–800 of 1,676
Warden, B. A., Minnier, J., Watts, G. F., Fazio, S., & Shapiro, M. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.008 · Cited by 22
Lp(a): Addressing a Target for Cardiovascular Disease Prevention
Vasquez, N., & Joshi, P. H. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1182-0 · Cited by 20
Effect of niacin monotherapy on high density lipoprotein composition and function
Gordon, S. M., Amar, M. J., Jeiran, K., Stagliano, M. S., Staller, E., Playford, M. P., Mehta, N. N., Vaisar, T., & Remaley, A. T. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01350-3 · Cited by 21
Zhang, Y., Li, J., Liu, C., Yu, H., Chen, C., Bi, C., Fang, C., Ma, H., Li, A., Dong, Q., et al. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s295252 · Cited by 23
“Furthermore, no significant reduction in CVD was observed including IS events in the AIM-HIGH and HPS2-THRIVE studies in association with HDL-C levels.(16,17) However, these studies evaluated patients with a history of CVD.”
BackgroundMooradian, A. D. (2016) · Drugs · doi:10.1007/s40265-016-0609-9 · Cited by 22
“Although dyslipidemia of diabetes is strongly linked to the pathogenesis of vascular disease, only statins had been consistently shown to have vascular protective effects [93, 115, 116].”
BackgroundHDL-cholesterol, genetics, and coronary artery disease: the myth of the ‘good cholesterol’?
Landmesser, U., & Hazen, S. L. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy299 · Cited by 20
Langlois, M. R., & Nordestgaard, B. G. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1036-1 · Cited by 19
Lipoprotein(a) – From Biomarker to Therapy: A Review for the Clinician
Jha, M., Raber, I., & Gelfand, E. V. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.02.034 · Cited by 22
Cholesteryl Ester Transfer Protein Inhibitors: Trials and Tribulations
McLain, J. H., Alsterda, A. J., & Arora, R. R. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416662349 · Cited by 23
“The similar study Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) found that niacin therapy combined with statin therapy in patients with high CVD risk had no significant improvement over statin therapy alone.(14) Recent studies on rare SR-B1 variants have also shown…”
ResultCao, Y., Rajan, S. S., & Wei, P. (2016) · Genetic Epidemiology · doi:10.1002/gepi.22013 · Cited by 27
“In addition, RCTs have shown that HDL increasing therapy does not reduce cardiovascular risk (Landray et al., 2014) The limitation of this work is that the two new proposed methods are only aimed for hypothesis testing, not for causal effect size estimation.”
BackgroundCan we revive CETP-inhibitors for the prevention of cardiovascular disease?
Nicholls, S. J., Ray, K. K., Nelson, A. J., & Kastelein, J. J. P. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000854 · Cited by 19
Fularski, P., Hajdys, J., Majchrowicz, G., Stabrawa, M., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031637 · Cited by 28
“It is estimated that fibrates are able to reduce the TGs levels by up to 50%, the LDL-C levels by ≤ 20% and increase the HDL-C levels by ≤ 20% [154].”
BackgroundMontecucco, F., Lenglet, S., Carbone, F., Boero, S., Pelli, G., Burger, F., Roth, A., Bertolotto, M. B., Nencioni, A., Cea, M., et al. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.04.008 · Cited by 19
la Paz, S. M., Naranjo, M. C., López, S., Abia, R., Muriana, F. J. G., & Bermúdez, B. (2016) · Food & Function · doi:10.1039/c6fo00381h · Cited by 19
Pharmacological Effects of Niacin on Acute Hyperlipemia
la Paz, S. M., Bermúdez, B., Naranjo, M. C., López, S., Abia, R., & Muriana, F. J. G. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160411142909 · Cited by 21
Chang, Y., Zhou, S., Li, E., Zhao, W., Ji, Y., Wen, X., Sun, H., & Yuan, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.098 · Cited by 19
Wiesner, P., & Watson, K. E. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.03.004 · Cited by 29
PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives
Fitzgerald, G., & Kiernan, T. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1497975 · Cited by 21
Schooling, C. M., & Ng, J. C. M. (2019) · SSM - Population Health · doi:10.1016/j.ssmph.2019.100411 · Cited by 22
“Moreover, several treatments targeting wellestablished CVD risk factors, such as lipids, have failed in late-stage randomized controlled trials (RCTs) (Armitage, Holmes, & Preiss, 2019; Canner et al., 1986; Landray et al., 2014).”
BackgroundLipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations
Pearson, K., & Rodríguez, F. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00177-4 · Cited by 20
Trivedi, K., Le, V. T., & Nelson, J. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1783937 · Cited by 21
“In the Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), the niacin group not only failed to achieve its primary CV endpoint, but had an increased risk of serious AEs [117,118].”
BackgroundStatins, atherosclerosis regression and HDL: Insights from within the plaque
Feig, J. E., Feig, J. L., & Kini, A. S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.036 · Cited by 19
“This idea is consistent with recent studies in which the plasma level of HDL-C was raised pharmacologically (e.g., AIM-HIGH [32], ILLUMINATE [33], dal-OUTCOMES [34,35], and HPS2-THRIVE [36]) without evidence that there were any reductions in cardiovascular events.”
BackgroundUse of Run-in Periods in Randomized Trials
Huo, X., & Armitage, J. (2020) · JAMA · doi:10.1001/jama.2020.6463 · Cited by 21
Pelacarsen: Mechanism of action and Lp(a)-lowering effect
Bhatia, H. S., Bajaj, A., Goonewardena, S. N., & Moriarty, P. M. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.004 · Cited by 43
Ferrières, J., Bataille, V., Puymirat, É., Schiele, F., Simon, T., Danchin, N., & for the FAST‐MI investigators (2020) · Clinical Cardiology · doi:10.1002/clc.23437 · Cited by 20
New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
Nestel, P. J., Loh, W. J., Ward, N. C., & Watts, G. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac541 · Cited by 21
Chen, J., Zhao, F., Lei, C., Qi, T., Xue, X., Meng, Y., Zhang, W., Zhang, H., Wang, J., Zhu, H., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.999224 · Cited by 21
“Second, some patients cannot tolerate statins (Reiner, 2018); this has been particularly identified in Chinese patients who are administered high-dose statins (Group et al., 2014).”
BackgroundLi, Z., Zou, X., Lu, R., Wan, X., Sun, S., Wang, S., Qu, Y., Zhang, Y., Li, Z., Yang, L. M., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111452 · Cited by 20
Adverse Drug Reaction reports for cardiometabolic drugs from sub‐Saharan Africa: a study in VigiBase
Berhe, D. F., Juhlin, K., Star, K., Beyene, K. G. M., Dheda, M., Haaijer‐Ruskamp, F. M., Taxis, K., & Mol, P. G. M. (2015) · Tropical Medicine & International Health · doi:10.1111/tmi.12481 · Cited by 17
“The other group of drugs may be drugs for which in the RoW more reports were received possibly because the attention they received of highly publicised safety concerns (rosiglitazone) or actually a lack of efficacy (nicotinic acid) [30, 31, 32].”
BackgroundLipoprotein(a): A Lipoprotein Whose Time Has Come
Kelly, E. M., & Hemphill, L. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0549-z · Cited by 20
Sakamoto, K., Kawamura, M., Watanabe, T., Ashidate, K., Kohro, T., Tanaka, A., Mori, Y., Tagami, M., Hirano, T., Yamazaki, T., et al. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0508-4 · Cited by 19
“Extended-release niacin offers no beneficial effects on CV events and is reported to trigger serious adverse events in subjects with diabetes and to increase the risks of the newly onset DM [4, 5].”
BackgroundMark, P. B., Winocour, P. H., & Day, C. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.125 · Cited by 18
Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkinstian, A., Reid, C. M., Wongcharoen, W., & Chaiyakunapruk, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00547 · Cited by 19
“Some agents were shown to have neutral effects (Barter et al., 2007a; Ginsberg et al., 2010; Kromhout et al., 2010; Boden et al., 2011; Schwartz et al., 2012; Landray et al., 2014) while some agents were shown to reduce some forms of cardiovascular outcomes (Yokoyama et al.”
BackgroundResultInfluence of lipid-lowering drugs on inflammation: what is yet to be done?
Ugovšek, S., Zupan, J., Likozar, A. R., & Šebeštjen, M. (2021) · Archives of Medical Science · doi:10.5114/aoms/133936 · Cited by 21
“Furthermore, the niacin plus laropiprant treatment increased the incidence of diabetes and serious adverse events [49].”
BackgroundMethodWhat an anticardiovascular diet should be in 2015
Jacobs, D. R., & Tapsell, L. C. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000184 · Cited by 19
“A recent clinical trial of niacin and the antiflushing agent laropiprant found adverse effects for infection, bleeding, and diabetes, among other effects [13].”
BackgroundEnfermedad renal crónica y dislipidemia
Pascual, V., Serrano, A., Pedro‐Botet, J., Ascaso, J. F., Barrios, V., Millán, J., Pintó, X., & Cases, A. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.07.004 · Cited by 31
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
Li, B., Luo, Y., Tian, F., Chen, Y., Tian, J., Ding, Y., Mei, Z., Li, J., Zhang, Y.-Q., & Shi, W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.015 · Cited by 17
Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus
Müller, M., Schönfeld, C., Grammer, T. B., Krane, V., Drechsler, C., Genser, B., Kohnen, T., Wanner, C., & März, W. (2020) · Scientific Reports · doi:10.1038/s41598-020-70998-9 · Cited by 21
Environmental Factors Modifying HDL Functionality
Kostara, C. E., Kosmas, C. E., Sourlas, A., & Guzman, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210714155422 · Cited by 18
Sokołowska, M., Rovati, G. E., Diamant, Z., Untersmayr, E., Schwarze, J., Łukasik, Z. M., Sava, F., Angelina, A., Palomares, Ó., Akdiş, C. A., et al. (2022) · Allergy · doi:10.1111/all.15258 · Cited by 18
Dugré, N., Lindblad, A. J., Perry, D., Allan, G. M., Braschi, É., Falk, J., Froentjes, L. S., Garrison, S., Kirkwood, J. E. M., Korownyk, C. S., et al. (2023) · Canadian Family Physician · doi:10.46747/cfp.6910701 · Cited by 25
“Most trials examined secondary cardiovascular prevention and approximately 70% of all participants were from the HPS2-THRIVE trial (Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events), 88 which found no benefit of adding niacin to a statin.”
BackgroundMedications for Lipid Control: Statins vs Newer Drugs
McPherson, R., Adreak, N., & Sharma, A. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.05.004 · Cited by 33
Krempf, M., Simpson, R. J., Ramey, D. R., Brudi, P., Giezek, H., Tomassini, J. E., Lee, R., & Farnier, M. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0037-y · Cited by 18
“It is likely that the conservative approach to use of combination therapy seen in clinical practice has, until recently, reflected a lack of confidence amongst physicians in the clinical benefit of LDL-C-lowering by combination therapy due to lack of evidence showing benefits on CVD-related events in outcome trials –…”
ResultPraluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia.
Raedler, L. A. (2016) · Europe PMC (PubMed Central) · Cited by 27
Honda, S., Sidharta, S. L., Shishikura, D., Takata, K., Giovanni, G. D., Nguyen, T., Janssan, A., Kim, S. W., Andrews, J., Psaltis, P. J., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.016 · Cited by 19
Antibodies against HDL Components in Ischaemic Stroke and Coronary Artery Disease
Batuca, J. R., Amaral, M., Favas, C., Justino, G. C., Papoila, A. L., Ames, P. R. J., & Alves, J. D. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1645857 · Cited by 17
Parolini, C., Adorni, M. P., Busnelli, M., Manzini, S., Cipollari, E., Favari, E., Lorenzon, P., Ganzetti, G. S., Fingerle, J., Bernini, F., et al. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.05.033 · Cited by 20
Therapeutic management of hyperlipoproteinemia (a)
Kosmas, C. E., Sourlas, A., Mallarkey, G., Silverio, D., Garcia, D. Y., Montan, P. D., Guzman, E., & Garcia, M. J. (2019) · Drugs in Context · doi:10.7573/dic.212609 · Cited by 19
Liu, W., Lü, X., Jiang, M., Wu, F., Tian, J., Yu, L., & Wen, H. (2019) · Aquaculture Reports · doi:10.1016/j.aqrep.2019.100243 · Cited by 19
Nakazawa, M., Arashi, H., Yamaguchi, J., Ogawa, H., & Hagiwara, N. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.05.005 · Cited by 18
Jarr, K.-U., Ye, J., Kojima, Y., Nanda, V., Flores, A. M., Tsantilas, P., Wang, Y., Hosseini-Nassab, N., Eberhard, A. V., Lotfi, M., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315239 · Cited by 20
Zou, J., Tian, Z., Zhao, Y., Qiu, X., Mao, Y.-H., Li, K., Shi, Y., Zhao, D., Liang, Y. J., Ji, Q., et al. (2022) · Nutrition · doi:10.1016/j.nut.2022.111703 · Cited by 19
Gebhard, C., Rhainds, D., He, G., Rodés‐Cabau, J., Lavi, S., Spence, J. D., Title, L. M., Kouz, S., L’Allier, P. L., Grégoire, J. C., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.025 · Cited by 16
on behalf of the SHARP Collaborative Group, Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0545-2 · Cited by 16
“However, similar intention-totreat analyses of non-adjudicated, non-vascular SAEs have previously been used to demonstrate both known and previously unrecognised hazards of niacin in the large-scale HPS2-THRIVE trial [47].”
ResultMarkossian, T. W., Burge, N. J., Ling, B., Schneider, J., Pacold, I. V., Bansal, V., Leehey, D. J., Stroupe, K. T., Chang, A. R., & Kramer, H. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.030 · Cited by 17
Genomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment
Li, C., Pan, Y., Zhang, R., Huang, Z., Li, D., Han, Y., Larkin, C. T., Rao, V., Sun, X., & Kelly, T. N. (2023) · Circulation Research · doi:10.1161/circresaha.123.321999 · Cited by 22
High density lipoprotein: When to rethink too much of a good thing
Dastmalchi, L. N., German, C. A., & Taub, P. R. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100511 · Cited by 22
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
Preta, G. (2023) · Cells · doi:10.3390/cells12202466 · Cited by 19
HDL as a Treatment Target: Should We Abandon This Idea?
Bègue, F., Apalama, M. L., Lambert, G. C., & Meilhac, O. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01176-1 · Cited by 16
When cardiovascular medicines should be discontinued
Krychtiuk, K. A., Gersh, B. J., Washam, J. B., & Granger, C. B. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae302 · Cited by 21
Targeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance
Mooradian, A. D., & Haas, M. J. (2015) · Drugs · doi:10.1007/s40265-015-0390-1 · Cited by 16
“RVX-208 is a ligand for the bromodomain and extra AIM-HIGH [31] A total of 3414 patients with atherosclerotic cardiovascular disease and LDLc levels of\70 mg/dl Extended-release niacin, 1500–2000 mg/day, or matching placebo At 2 years, niacin had significantly increased the median HDLc level from 35 to 42 mg/dl, lower…”
MethodInfluentialHagström, E., Roe, M. T., Hafley, G. E., Neely, M. L., Sidhu, M. S., Winters, K. J., Prabhakaran, D., White, H. D., Armstrong, P. W., Fox, K. A. A., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22533 · Cited by 21
O’Keefe, J. H., DiNicolantonio, J. J., & Lavie, C. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.11.001 · Cited by 17
“Multiple large and definitive studies show that despite significant improvement in HDL-C levels, niacin, fibrates and the cholesterol ester transfer protein inhibitors do not significantly reduce adverse outcomes (and on the balance may cause more harm than benefit).(17,18) Non-HDL cholesterol , and/or Apo B levels ar…”
BackgroundHancock-Cerutti, W. F., Lhomme, M., Dauteuille, C., Lecocq, S., Chapman, M. J., Rader, D. J., Kontush, A., & Cuchel, M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.018 · Cited by 18
Imaging as a surrogate marker of drug efficacy in cardiovascular disease
Tarkin, J. M., Dweck, M. R., & Rudd, J. H. F. (2018) · Heart · doi:10.1136/heartjnl-2017-311213 · Cited by 18
Effects of weight change on HDL-cholesterol and its subfractions in over 28,000 men and women
Dansinger, M. L., Williams, P. T., Superko, H. R., Asztalos, B. F., & Schaefer, E. J. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.12.001 · Cited by 19
Lipoprotein(a)—antisense therapy
Vogt, A. (2019) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-019-00096-2 · Cited by 16
Aguilar-Ramirez, D. J., Alegre-Díaz, J., Herrington, W. G., Staplin, N., Ramírez-Reyes, R., Gnatiuc, L., Hill, M., Romer, F., Torres, J., Trichia, E., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab497 · Cited by 16
Challenges in Optimizing Lipid Management in Women
Peterson, K., Kaur, G., Gianos, E., Mookherjee, S., Poli, K. A., Sidhu, M. S., & Lyubarova, R. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07273-0 · Cited by 20
HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis.
Mani, P., Uno, K., Duong, M., Wolski, K., Spalding, S., Husni, M. E., & Nicholls, S. J. (2016) · PubMed · doi:10.3978/j.issn.2223-3652.2015.12.14 · Cited by 17
“However, disappointing results of clinical trials of HDL raising agents (8-11) and a lack of association between genetic polymorphisms regulating HDL cholesterol levels and cardiovascular risk (12,13) have dampened enthusiasm for the HDL hypothesis.”
BackgroundStatin Combination Therapy and Cardiovascular Risk Reduction
Toth, P. P., Farnier, M., Tomassini, J. E., Foody, J. M., & Tershakovec, A. M. (2016) · Future Cardiology · doi:10.2217/fca-2015-0011 · Cited by 17
Mendes, D., Alves, C., & Marques, F. B. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1217989 · Cited by 17
Li, X., Wang, A., Wang, J., Wu, J., Wang, D., Gao, X., Wu, S., & Zhao, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-00596-9 · Cited by 17
Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys
Brodeur, M. R., Rhainds, D., Charpentier, D., Mihalache-Avram, T., Mecteau, M., Brand, G., Chaput, E., Perez, A., Niesor, E. J., Rhéaume, É., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m068940 · Cited by 18
Kiyosue, A. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.09.001 · Cited by 18
Janghorbani, M., Soltanian, N., Amini, M., & Aminorroaya, A. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.04.019 · Cited by 20
High-density lipoprotein (HDL) cholesterol – more complicated than we think?
Nessler, K., Windak, A., Grzybczak, R., Nessler, M. B., Siniarski, A., & Gajos, G. (2018) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/92350 · Cited by 18
“A recent study, HPS2-Thrive, has reported that the addition of niacin to statin-based LDL-C-lowering therapy did not significantly reduce the risk of major vascular events, but it did increase the risk of serious adverse events (such as gastrointestinal complications, bleeding, musculoskeletal side effects, or increas…”
BackgroundBaum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 16
Ferchaud‐Roucher, V., Croyal, M., Moyon, T., Zaïr, Y., Krempf, M., & Ouguerram, K. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6737-y · Cited by 17
“Recent cardiovascular outcome studies have reported that ERN treatment [46, 47] in addition to statin treatment does not provide any cardiovascular beneficial effects.”
BackgroundPatel, P. N., & Giugliano, R. P. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.39 · Cited by 24
Warren, R. A., Carew, A. S., Andreou, P., Herman, C. R., Levy, A. P., Ginsberg, H. N., Sapp, J. L., Rimm, E. B., Kirkland, S., & Cahill, L. E. (2021) · Diabetes Care · doi:10.2337/dc21-1429 · Cited by 15
NAD+-Increasing Strategies to Improve Cardiometabolic Health?
Blanco‐Vaca, F., Rotllán, N., Canyelles, M., Mauricio, D., Escolá‐Gil, J. C., & Julve, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.815565 · Cited by 16
“Interestingly, the percentage of men in the AIM-HIGH (9) andHPS-THRIVE (10) trials was around 85%.”
BackgroundResultThe role of HDL- and non-HDL-related parameters in cell-cholesterol efflux capacity
Asztalos, B. F., Hauser, T. H., Goldfine, A. B., Welty, F. K., Horvath, K. V., & Schaefer, E. J. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.02.012 · Cited by 17
Barbagelata, L., Masson, W. M., Corral, P., Cobo, A. L., Nogueira, J. P., & Diez, G. R. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01590-3 · Cited by 17
“However, clinical trials with these agents did not show a reduction of major cardiovascular events, and currently their use is not recommended [33].”
BackgroundSucato, V., Ortello, A., Comparato, F., Novo, G., & Galassi, A. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071882 · Cited by 24
Kumarapperuma, H., Chia, Z.-J., Malapitan, S. M., Wight, T. N., Little, P. J., & Kamato, D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118552 · Cited by 21
Niacin-induced flushing: Mechanism, pathophysiology, and future perspectives
Javaid, A., & Mudavath, S. L. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110163 · Cited by 19
Patial, S., Sharma, A., Raj, K., & Shukla, G. (2024) · The Microbe · doi:10.1016/j.microb.2024.100212 · Cited by 25
Robinson, J. G., & Ray, K. K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.306887 · Cited by 15
Managing dyslipidaemia in type 2 diabetes mellitus
Szalat, A., Durst, R. Y., & Leitersdorf, E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.05.004 · Cited by 21
Adhyaru, B. B., & Jacobson, T. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0666-x · Cited by 16
KEECH, A. C., & Jenkins, A. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000465 · Cited by 14
An updated review of lipid‐modifying therapy
Simons, L. A. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50142 · Cited by 18
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 16
Parthymos, I., Kostapanos, M. S., Mikhailidis, D. P., & Florentin, M. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab052 · Cited by 15
Why do statins reduce cardiovascular disease more than other lipid modulating therapies?
Schooling, C. M., Yeung, S. L. A., & Leung, G. M. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12342 · Cited by 16
Does the LDL Receptor Play a Role in the Risk of Developing Type 2 Diabetes?
Preiss, D., & Sattar, N. A. (2015) · JAMA · doi:10.1001/jama.2015.1275 · Cited by 18
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.